-
公开(公告)号：US20220274982A1
公开(公告)日：2022-09-01
申请号：US17630840
申请日：2020-07-28
Applicant: Takeda Pharmaceutical Company Limited
Inventor： Yuta TANAKA , Yuta TANAKA , Fumiaki KIKUCHI , Takeshi YAMAMOTO , Minoru NAKAMURA , Kazuaki TAKAMI , Masataka MURAKAMI , Masaki DAINI , Yasufumi WADA , Keiko KAKEGAWA , Takahito KASAHARA , Tomohiro OHASHI , Junsi WANG , Zenichi IKEDA , Florian PUENNER , Masaki SETO , Satoshi MIKAMI , Minoru SASAKI
IPC: C07D471/04
Abstract: The present invention provides a compound having a glucosylceramide synthase inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of lysosomal storage diseases (e.g., Gaucher's disease, Fabry's disease, GM1-gangliosidosis, GM2 activator deficiency, Tay-Sachs disease, Sandhoffs disease), neurodegenerative diseases (e.g., Parkinson's disease, Lewy body dementia, multiple-system atrophy) and the like.
The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof.-
公开(公告)号：US20180303841A1
公开(公告)日：2018-10-25
申请号：US15769295
申请日：2016-10-19
Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventor： Takahiro SUGIMOTO , Shinkichi SUZUKI , Hiroki SAKAMOTO , Masami YAMADA , Minoru NAKAMURA , Makoto KAMATA , Kenichiro SHIMOKAWA , Masaki OGINO , Eiji KIMURA , Masataka MURAKAMI , Takuto KOJIMA , Jinichi YONEMORI
CPC classification number: A61K31/53 , A61K31/517 , A61P25/04 , A61P25/16 , A61P25/18 , A61P25/28 , C07D239/88 , C07D401/06 , C07D401/14 , C07D403/06 , C07D403/10 , C07D405/14
Abstract: The present invention provides a compound which has a cholinergic muscarinic M1 receptor positive allosteric modulator activity and may be useful as a medicament such as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, Lewy body dementia and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof. In the formula (I), each symbol is as described in the attached specification.
-
公开(公告)号：US20170216255A1
公开(公告)日：2017-08-03
申请号：US15488002
申请日：2017-04-14
Applicant: Takeda Pharmaceutical Company Limited
Inventor： Masami YAMADA , Shinkichi SUZUKI , Takahiro SUGIMOTO , Minoru NAKAMURA , Hiroki SAKAMOTO , Makoto KAMATA
IPC: A61K31/4035 , A61K31/55 , A61K31/4439 , A61K31/325 , A61K31/4155 , A61K31/445 , A61K31/13
CPC classification number: C07D405/14 , A61K31/045 , A61K31/13 , A61K31/325 , A61K31/4035 , A61K31/4155 , A61K31/4406 , A61K31/4439 , A61K31/445 , A61K31/55 , C07D209/46 , C07D401/06 , C07D401/10 , C07D401/14 , C07D403/04 , C07D403/10 , C07D405/04 , C07D471/04
Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity and useful as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies, and the like.The present invention relates to a compound represented by the formula (I) or a salt thereof. wherein each symbol is as described in the specification, or a salt thereof.
-
公开(公告)号：US20240217957A1
公开(公告)日：2024-07-04
申请号：US18522917
申请日：2023-11-29
Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventor： Asato KINA , Zenichi IKEDA , Mitsunori KONO , Yuya OGURO , Osamu KUBO , Toru YAMASHITA , Kazuaki TAKAMI , Takafumi YUKAWA , Masaki SETO , Makoto KAMATA , Kenjiro SATO , Masataka MURAKAMI , Yusuke SASAKI , Matthew Thomas REYNOLDS , Minoru NAKAMURA , Taku KAMEI , Hiroyuki KAKEI , Fumie YAMAGUCHI , Tomohiro OHASHI , Takuto KOJIMA , Keiko KAKEGAWA , Florian PÜNNER , Shinji NAKAMURA , Nao MORISHITA , Tadashi HIDAKA , Sachie TAKASHIMA , Takahiko TANIGUCHI
IPC: C07D413/04 , A61P25/00 , C07D413/14
CPC classification number: C07D413/04 , A61P25/00 , C07D413/14
Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. Provided is a compound of formula (I):
wherein each symbol is as described in the specification, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.-
公开(公告)号：US20230357220A1
公开(公告)日：2023-11-09
申请号：US17999514
申请日：2021-05-20
Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventor： Tomoaki HASUI , Satoshi MIKAMI, JR. , Toru YAMASHITA , Shinji NAKAMURA , Shinji MORIMOTO , Toshihiro IMAEDA , Kazuaki TAKAMI , Masaki DAINI , Hiroyuki KAKEI , Minoru NAKAMURA , Fumie YAMAGUCHI , Chunxiang WANG , Sachie TAKASHIMA , Makoto KAMATA , Yuya OGURO , Shuhei IKEDA
IPC: C07D413/14 , C07D405/14 , C07D401/14
CPC classification number: C07D413/14 , C07D401/14 , C07D405/14
Abstract: Abstract: The present invention refers to compounds of formula (I). The present invention also relates to compounds of formula (I) for use as G Protein coupled Receptor 139 (GPR139) antagonists in methods of medical treatment of e.g. depression, Alzheimer’s disease, schizophrenia, drug addiction, sleep disorders, pain, and attention deficit hyperactivity disorder. Exemplary compounds are e.g. 3-((1H-pyrazol-4-yl)methyl)-6′-(phenyl)-2H-(1,2′-bipyridin)-2-one derivatives and related compounds. The present description discloses the synthesis and characterisation of exemplary compounds, pharmacological data thereof, as well as exemplary tablet formulations comprising the compounds of the invention (e.g. page 83 to page 110; examples 1 to 33; reference example 1; test examples 1 and 2; tables 1 to 4).
-
Patent Agency Ranking
公开(公告)号：US20230150934A1
公开(公告)日：2023-05-18
申请号：US18087233
申请日：2022-12-22
Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventor： Shuhei IKEDA , Makoto KAMATA , Yuya OGURO , Jumpei AIDA , Taisuke TAWARAISHI , Takeshi WAKABAYASHI , Norio OYABU , Atsuko OCHIDA , Kouichi IWANAGA , Satoshi YAMAMOTO , Masataka MURAKAMI , Minoru NAKAMURA , Fumie YAMAGUCHI , Takafumi YUKAWA
IPC: C07D207/263 , A61P25/18 , C07D401/06
CPC classification number: C07D207/263 , A61P25/18 , C07D401/06
Abstract: A compound of formula (I), or a salt thereof that may have an antagonistic action against an NMDA receptor that includes an NR2B subunit and may be useful as a prophylactic or therapeutic agent for depression, bipolar disorder, migraine, pain, a symptom peripheral to dementia, or the like.
-
公开(公告)号：US20230002318A1
公开(公告)日：2023-01-05
申请号：US17755907
申请日：2020-11-12
Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventor： Shuhei IKEDA , Makoto KAMATA , Yuya OGURO , Jumpei AIDA , Taisuke TAWARAISHI , Takeshi WAKABAYASHI , Norio OYABU , Atsuko OCHIDA , Kouichi IWANAGA , Satoshi YAMAMOTO , Masataka MURAKAMI , Minoru NAKAMURA , Fumie YAMAGUCHI , Takafumi YUKAWA
IPC: C07D207/263 , C07D401/06 , A61P25/18
Abstract: A compound of formula (I), or a salt thereof that may have an antagonistic action against an NMDA receptor that includes an NR2B subunit and may be useful as a prophylactic or therapeutic agent for depression, bipolar disorder, migraine, pain, a symptom peripheral to dementia, or the like.
-
公开(公告)号：US20210009572A1
公开(公告)日：2021-01-14
申请号：US17038917
申请日：2020-09-30
Applicant: Takeda Pharmaceutical Company Limited
Inventor： Masami YAMADA , Shinkichi SUZUKI , Takahiro SUGIMOTO , Minoru NAKAMURA , Hiroki SAKAMOTO , Makoto KAMATA
IPC: C07D405/14 , C07D209/46 , C07D401/10 , C07D401/14 , C07D403/04 , C07D403/10 , C07D401/06 , C07D405/04 , A61K31/4035 , A61K31/4155 , A61K31/4439 , A61K31/13 , A61K31/325 , A61K31/445 , A61K31/55 , A61K31/045 , A61K31/4406
Abstract: The present invention provides a compound having a cholinergic muscarinic Ml receptor positive allosteric modulator activity and useful as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies, and the like.
The present invention relates to a compound represented by the formula (I) or a salt thereof. wherein each symbol is as described in the specification, or a salt thereof.-
公开(公告)号：US20170283406A1
公开(公告)日：2017-10-05
申请号：US15474192
申请日：2017-03-30
Applicant: Takeda Pharmaceutical Company Limited
Inventor： Shuhei Ikeda , Hideyuki SUGIYAMA , Jumpei AIDA , Hidekazu TOKUHARA , Tomohiro OKAWA , Yuya OGURO , Minoru NAKAMURA , Masataka MURAKAMI
IPC: C07D413/14 , C07D413/08 , C07D405/14 , C07D401/08
CPC classification number: C07D413/14 , C07D401/06 , C07D401/08 , C07D405/14 , C07D413/06 , C07D413/08
Abstract: The present invention provides a compound having an MAGL inhibitory action, and useful as an agent for the prophylaxis or treatment of neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, traumatic brain injury, glaucoma, multiple sclerosis etc.), anxiety disorder, pains (e.g., inflammatory pain, cancerous pain, neurogenic pain etc.), epilepsy, depression and the like.The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.
-
公开(公告)号：US20170266162A1
公开(公告)日：2017-09-21
申请号：US15608557
申请日：2017-05-30
Applicant: Takeda Pharmaceutical Company Limited
Inventor： Masami YAMADA , Shinkichi SUZUKI , Takahiro SUGIMOTO , Minoru NAKAMURA , Hiroki SAKAMOTO , Makoto KAMATA
IPC: A61K31/4035 , A61K31/55 , A61K31/13 , A61K31/325 , A61K31/4155 , A61K31/445 , A61K31/4439
CPC classification number: C07D405/14 , A61K31/045 , A61K31/13 , A61K31/325 , A61K31/4035 , A61K31/4155 , A61K31/4406 , A61K31/4439 , A61K31/445 , A61K31/55 , C07D209/46 , C07D401/06 , C07D401/10 , C07D401/14 , C07D403/04 , C07D403/10 , C07D405/04 , C07D471/04
Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity and useful as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies, and the like.The present invention relates to a compound represented by the formula (I) or a salt thereof. wherein each symbol is as described in the specification, or a salt thereof.
-
-
-
-
-
-
-
-
-
Search Results
39
records
(took 0.032 seconds)
